Health ❯ Clinical Trials

Drug Efficacy

Weight Loss Drugs Weight Loss Studies Weight Loss ESSENCE Trial Phase 3 Trials Patient Outcomes Cardiovascular Health Phase Trials Dosing Strategies FDA Approval Orforglipron Antiretroviral Drugs Regulatory Challenges Linzagolix Anti-fibrotic Treatments Toxicity Studies Mounjaro Trials Biomarkers Preventive Treatments Weight Loss Treatments Ruxolitinib Infection Prevention Medical Needs Type 1 Diabetes Treatment Compounded Medications Research Studies Survival Rates HIV Research GLP-1 Therapies Ozempic Trials BCR::ABL1 Inhibitors Medical Results Safety and Tolerability Lenacapavir Studies

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

The ruling follows phase 3 data showing longer survival with relacorilant plus nab-paclitaxel.

For Third Time, FDA Rejects Aldeyra’s Dry-Eye Drug Reproxalap Over Efficacy

NICE Recommends First Vitiligo Repigmentation Cream for NHS Use in England

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

Small Molecule Blocks RAGE–DIAPH1 Pathway, Reduces Diabetic Tissue Damage in Mice

South Africa Approves Twice-Yearly HIV Prevention Shot, Clearing Path to 2026 Rollout

Amgen Reports Repatha Cuts First-Event Risk in Primary-Prevention Trial

Roche to Acquire 89bio in Deal Worth Up to $3.5 Billion

Maze Therapeutics Reports Strong Phase 1 Signal for MZE782, Announces $150 Million Private Placement

WHO Endorses Twice-Yearly HIV Prevention Jab as Early Adopters Plan 2026 Rollout